PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer

Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, describes the trial design of the phase I PRINCE trial (NCT03658447), which assessed 177Lu-PSMA-617, a PSMA-targeted radioligand therapy, plus pembrolizumab for patients with metastatic castration resistant prostate cancer (mCRPC). A majority of these patients will have progressed on existing therapies such as docetaxel, and the trial will additionally ascertain the efficacy of circulating tumour cells (CTCs) and PSMA positron emission tomography (PET) scans as biomarkers of prognosis. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.